Neuro-ophthalmologic manifestations of sarcoidosis

Current Treatment Options in Neurology

Volumn 9, Issue 1, 2007, Pages 63-71

  Stern, Barney J ^a   Corbett, James ^b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADALIMUMAB; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; AZATHIOPRINE; BARBITURIC ACID DERIVATIVE; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ETANERCEPT; FOLIC ACID; GADOLINIUM; HYDROXYCHLOROQUINE; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NONSTEROID ANTIINFLAMMATORY AGENT; PENTOXIFYLLINE; PHENOBARBITAL; PHENYTOIN; PREDNISONE; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA;

ADJUVANT THERAPY; ALCOHOLIC BEVERAGE; BIOPSY; BIRTH DEFECT; BLOOD CELL COUNT; BLOOD DISEASE; BLOOD TOXICITY; CATARACT; CHRONIC DRUG ADMINISTRATION; CLINICAL FEATURE; COST EFFECTIVENESS ANALYSIS; DEMYELINATING DISEASE; DIABETES MELLITUS; DIET RESTRICTION; DOSE CALCULATION; DRUG ALCOHOL INTERACTION; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG COST; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG ERUPTION; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG INHIBITION; DRUG MEGADOSE; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG TOLERABILITY; EYE DISEASE; GASTROINTESTINAL SYMPTOM; HUMAN; INFECTION RESISTANCE; INFLAMMATION; KINESIOTHERAPY; LEUKOCYTE COUNT; LEUKOPENIA; LIPOMATOSIS; LIVER CIRRHOSIS; LIVER FUNCTION; LUNG FIBROSIS; LYMPHADENOPATHY; MYOPATHY; NAUSEA; NEUROLOGIC DISEASE; NEUROOPHTHALMOLOGY; NEUTROPENIA; OPPORTUNISTIC INFECTION; OPTIC NERVE DISEASE; OPTIC NEURITIS; OSTEOPOROSIS; PATIENT MONITORING; PERIPHERAL NEUROPATHY; PHOTOSENSITIVITY; PHYSIOTHERAPY; REPEATED DRUG DOSE; RETINA INJURY; REVIEW; SARCOIDOSIS; SEIZURE; SENSORY NEUROPATHY; SIDE EFFECT; SPEECH THERAPY; SPINE DISEASE; THROMBOSIS; VOMITING; WEIGHT CONTROL; WEIGHT GAIN;

EID: 33847345463     PISSN: 10928480     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11940-007-0032-3     Document Type: Review

References (22)

1. Gullapalli D, Phillips LH II: Neurological manifestations of sarcoidosis. Neurol Clin 2002, 20:59-83.
2. Krumholz A, Stern BJ: Neurological manifestations of sarcoidosis. In Handbook of Clinical Neurology, Systemic Diseases, Part III. Edited by Vinkin PJ, Bruyn GW. Amsterdam: Elsevier; 1998:463-523.
3. Baughman RP, Teirstein AS, Judson MA, et al.: Clinical characteristics of patients in a case control study of sarcoidosis. A Case Control Etiologic Study of Sarcoidosis (ACCESS) research group. Am J Resp Crit Care Med 2001, 164:1885-1889.
4. Rybicki BA, Iannuzzi MC, Frederick MM, et al.: Familial aggregation of sarcoidosis: A Case-Control Etiologic Study of Sarcoidosis (ACCESS). The ACCESS Research Group. Am J Resp Crit Care Med 2001, 164:2085-2091.
5. Gal AA, Koss MN: The pathology of sarcoidosis. Curr Opin Pulm Med 2002, 8:445-451.
6. Nowak DA, Widenka DC: Neurosarcoidosis: a review of its intracranial manifestation. J Neurol 2001, 248:363-372.
7. Heuser, K, Kerty E: Neuroophthalmological findings in sarcoidosis. Acta Ophthalmol Scand 2004, 82:723-729.
8. Constantino T, Digre KB, Zimmerman P: Neuro-ophthalmic complications of sarcoidosis. Semin Neurol 2000, 20:123-135.
9. Zajicek JP, Scolding NJ, Foster O, et al.: Central nervous system sarcoidosis: diagnosis and management. Q J Med 1999, 92:103-117.
10. Johns CJ, Michele TM: The clinical management of sarcoidosis: a 50-year experience at the Johns Hopkins Hospital. Medicine 1999, 78:65-111.
11. Baughman RP: Therapeutic options for sarcoidosis: new and old. Curr Opin Pulm Med 2002, 8:464-469.
12. Ferriby D, de Seze J, Stojkovic T, et al.: Long-term follow-up of neurosarcoidosis. Neurology 2001, 57:927-929.
13. Pettersen JA, Zochodne DW, Bell RB, et al.: Refractory neurosarcoidosis responding to infliximab. Neurology 2002, 59:1660-1661.
14. Katz JM, Bruno MK, Winterkorn JMS, Nealon N: The pathogenesis and treatment of optic disc swelling in neurosarcoidosis: a unique therapeutic response to infliximab. Neurology 2003, 60:426-430.
15. Suhler EB, Smith JR, Wertheim MS, et al.: A prospective trial of infliximab therapy for refractory uveitis. Preliminary safety and efficacy outcomes. Arch Ophthalmol 2005, 123:903-912.
16. Heffernan MP, Smith DI: Adalimumab for treatment of cutaneous sarcoidosis. Arch Dermatol 2006, 142:17-19.
17. Agbogu BN, Stern BJ, Sewell C, Yang G: Therapeutic considerations in patients with refractory neurosarcoidosis. Arch Neurol 1995, 52:875-879.
18. Maust HA, Foroozan R, Sergott RC, et al.: Use of methotrexate in sarcoid associated optic neuropathy. Ophthalmology 2003, 110:559-563.
19. Kouba DJ, Mimouni D, Rencic A, Nousari HC: Mycophenolate mofetil may serve as a teroid-sparing agent for sarcoidosis. Br J Dermatol 2003, 148:147-148.
20. Meierhofer C, Dunzendorfer S, Wiedermann CJ: Theoretical basis for the activity of thalidomide. Biodrugs 2001, 15:681-703.
21. Baughman RP, Judson MA, Teirstein AS, et al.: Thalidomide for chronic sarcoidosis. Chest 2002, 122:227-232.
22. Baughman RP, Lower EE, Bradley DA, et al.: Etanercept for refractory ocular sarcoidosis. Results of a double-blind randomized trial. Chest 2005, 128:1062-1067.